https://charts.traderzeitung.de/phases/US45258J1025
string(1454) "{"isin":"US45258J1025","name":"Immunovant Inc","stock_id_xnas":10808991,"stock_id_xnys":10808987,"generated_at":"2026-07-10 20:38:00","days":[{"date":"2026-07-08","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":39.28,"close_at":"2026-07-08 15:29:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":40.3,"close_at":"2026-07-08 21:59:00","complete":true,"perf_pct":2.5967},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":40.23,"close_at":"2026-07-08 23:47:00","complete":true,"perf_pct":-0.1737}]},{"date":"2026-07-09","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":40.5,"close_at":"2026-07-09 13:57:00","complete":true,"perf_pct":0.6711},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":41.1,"close_at":"2026-07-09 21:59:00","complete":true,"perf_pct":1.4815},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-10","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":39.92,"close_at":"2026-07-10 20:38:00","complete":false,"perf_pct":-2.871},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Immunovant Aktie News & Nachrichten

Immunovant Aktie News & Nachrichten

[WKN: A2P5G1 | Symbol: IMVT]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Immunovant Chart
Trader-Zeitung Agentic 10.07.2026 15:30 Uhr

Immunovant-Aktie im Aufwind: LifeSci Capital hebt Kursziel nach Pipeline-Fokus kräftig an

Das US-Biotech-Unternehmen Immunovant steht wieder verstärkt im Fokus der Anleger. Der renommierte Analyst Sam Slutsky vom Analysehaus LifeSci Capital

MT Newswires 29.06.2026 09:33 Uhr

Immunovant Insider hat Aktien im Wert von $1.532.309 verkauft, laut einer aktuellen SEC-Einreichung

03:32 AM EDT, 06/29/2026 (MT Newswires) -- Jay S Stout, Chief Technology Officer, hat am 26. Juni 2026 40.000 Aktien von Immunovant (IMVT) für $1.532.

MT Newswires 26.05.2026 20:32 Uhr

JPMorgan erhöht Immunovant-Kursziel auf 47 $ von 35 $, "Overweight"-Rating beibehalten

02:32 PM EDT, 05/26/2026 (MT Newswires) -- Immunovant (IMVT) hat ein durchschnittliches "Kaufen"-Rating und ein mittleres Kursziel von 46,77 $, laut v